Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis by Pressler, Tacjana
© 2008 Dove Medical Press Limited.   All rights reserved
Biologics: Targets & Therapy 2008:2(4) 611–617 611
REVIEW
Review of recombinant human deoxyribonuclease 
(rhDNase) in the management of patients 
with cystic ﬁ  brosis
Tacjana Pressler




Pediatric Department, Rigshospitalet 
Blegdamsvej 9 2100 Copenhagen Ø 
Denmark
Email pressler@mail.dk
Abstract: The most important problem in cystic ﬁ  brosis (CF) lung disease is chronic airway 
inﬂ  ammation and infection, which starts early in life. To prevent severe lung damage, it is 
important to mobilize as much sputum as possible from the lung on a daily basis. RhDNase is 
an enzyme that breaks down DNA strands in airway secretions, hydrolyzes the DNA present in 
sputum/mucus of CF patients, reducing viscosity in the lungs and promoting secretion clearance. 
Several well performed trials have proven its efﬁ  cacy in young CF patients with mild disease as 
well as in older patients with more advanced lung disease. Daily inhalation of this agent slows 
down lung function decline and decreases the frequency of respiratory exacerbations. The drug 
is well tolerated by most patients independent of the severity of lung disease.
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Introduction
Cystic ﬁ  brosis (CF) is a hereditary disease caused by mutations in the gene coding 
for the CF transmembrane conductance regulator protein (CFTR) which is involved 
in transmembrane ion conductance (Riordan et al 1989; Rommens et al 1989). The 
primary defect involves ion imbalance resulting in inspissated exocrine secretions, 
particularly in the pancreas, lung, liver and gastrointestinal tract. At birth, the pri-
mary manifestation is failure to thrive and/or meconium ileus due to gastrointestinal 
involvement including, in most cases, pancreatic insufﬁ  ciency (Collins 1992; Riordan 
2008). Once the disease is diagnosed and pancreatic enzyme supplementation com-
bined with a high-fat diet begun, malnutrition can usually be avoided and the most 
troublesome symptoms are due to progressive pulmonary infection and inﬂ  ammation, 
which are promoted by typically viscous CF mucus in the lung. While the lungs of CF 
patients appear normal at birth, postmortem studies of lungs from infants who died of 
meconium ileus identiﬁ  ed mucus plugging in terminal bronchioles with emphysema 
secondary to obstruction of mucus ﬁ  lled bronchioles (Zuelzer et al 1949). A vicious 
circle ensues shortly after birth, characterized by thick mucus obstructing small air-
ways and thus providing a niche for bacterial growth, inﬁ  ltration of lung tissue by 
neutrophils as a component of the inﬂ  ammatory response, discharge of neutrophil 
contents including the viscous polyanion DNA, and increasingly viscous mucus. The 
abnormal mucus leads to chronic lower airway infection and inﬂ  ammation that starts 
mostly in infancy (Konstan et al 1994; Armstrong et al 1997; Rosenfeld et al 2001; 
Sagel et al 2001).
Extracellular DNA released by disintegrating inﬂ  ammatory cells, is present in 
high concentrations in CF sputum (Chernick 1959; Smith et al 1988). This free DNA 
contributes to the abnormally high viscosity of CF sputum. It therefore forms an impor-
tant target in the treatment of CF lung disease. Chronic infection and inﬂ  ammation Biologics: Targets & Therapy 2008:2(4) 612
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gradually reduce pulmonary function and induce irreversible 
lung damage. Double lung transplant is the only effective 
treatment in the terminal stages of CF lung disease. In 2006 
in US, the median predicted survival age was 36.9 years 
(Cystic Fibrosis Foundation 2006). Death is usually due to 
irreversible lung damage and cardiopulmonary failure.
Treatment of CF lung disease is still symptomatic and 
focused on antibiotic treatment of lung infections, and facili-
tating removal of abnormal pulmonary secretions (Döring 
et al 2004).
According to current understanding of the pathogenesis 
of CF pulmonary disease, airway damage is result of a 
vicious cycle of inﬂ  ammatory responses involving recruit-
ment of large numbers of leukocytes, primarily neutrophils 
(Koch et al 1993). When neutrophils disintegrate, they 
release high concentrations of extracellular DNA. Polymer-
ized DNA contributes to the increased viscosity of airways 
secretions. This free DNA contributes to the abnormally 
high viscosity of CF sputum. It therefore forms an important 
target in the treatment of CF lung disease. Impaired muco-
ciliary clearance is an important problem in most patients 
with CF. Consequently, a major goal in the treatment of CF 
is to mobilize as much sputum as possible from the lung on 
a daily basis.
Until now, two drugs are established with a positive effect 
on mucociliary clearance in patients with CF: recombinant 
human DNase (rhDNase) and hypertonic saline (Robinson 
et al 1997; Houtmeyers et al 1999; Ratjen et al 2005).
Biological rationale for rhDNAse 
therapy
The biological rationale for rhDNAse therapy relates to the 
observation that purulent pulmonary secretions contain high 
concentrations of extracellular DNA released by disintegrat-
ing neutrophils.
Experiments in the 1950s and 1960s revealed that DNA 
is present in very large amounts (3–14 mg/mL) in purulent, 
but not in uninfected, lung secretions (Chernick et al 1961; 
Potter et al 1969). DNA, an extremely viscous polyanion, 
may contribute to the increased viscosity of lung secretions. 
In fact, lung secretions incubated in vitro with partially 
puriﬁ  ed bovine pancreatic DNase show a large reduction 
in viscosity (Chernick et al 1961). Based on these observa-
tions, bovine pancreatic DNase I (dornavac or dornase) 
was approved in the US for human use in 1958. Numerous 
uncontrolled clinical studies in patients with pneumonia 
and one study in CF suggested that bovine pancreatic 
DNase I was reasonably safe and effective in reducing the 
viscosity of lung secretions (Lieberman 1968). However 
severe adverse respiratory reactions did occasionally occur, 
perhaps as a consequence of allergic reactions to a foreign 
protein.
The gene for human DNase was cloned from a pancreatic 
cDNA library in 1988 (Shak et al 1990) and the recombinant 
human DNase (rhDNase) has been synthesized. Because 
rhDNase is identical to human DNase, it can be used safely 
without risking the hazards associated with the use of ani-
mal proteins. Catalytic amounts of rhDNase greatly reduce 
the viscosity of purulent CF sputum, transforming it within 
minutes from a nonﬂ  owing viscous gel to a ﬂ  owing liquid 
(Shak et al 1990).
In a multicenter open study the evolution of inﬂ  am-
mation in CF patients with early lung disease and its 
modulation by rhDNase treatment, were studied (Ratjen 
et al 2005). Treatment with rhDNase over 18 months 
reduces DNA load in BAL ﬂ  uid, which may have a positive 
effect on the clearance of lower airway secretions (Ratjen 
et al 2005).
Safety of rhDNase treatment
The safety of rhDNase has been assessed with respect to 
clinical adverse events and laboratory parameters (Aitken 
et al 1992; Ramsey et al 1993; Eisenberg et al 1997). In 
phase I studies, serum rhDNase concentration was measured 
at several time points following single and multiple inhala-
tion of escalating doses of rhDNase in healthy subjects and 
in patients with CF. Only very low serum concentrations of 
DNase were observed. No anti-rhDNase antibodies were 
detected in each of the studies (Aitken et al 1992; Hubbard 
et al 1992). Therefore, it is concluded that systemic expo-
sure to inhaled rhDNase was negligible. Since rhDNase 
was marketed, multiple studies have been performed on this 
drug (Jones et al 2003). RhDNase is now widely used for 
treatment of CF lung disease. This gave the opportunity to 
use long-term clinical data from patient registries for post-
marketing surveillance. Hodson et al reported on rhDNase 
using the Epidemiologic Registry of Cystic Fibrosis (ERCF) 
(Hodson et al 2003; McKenzie et al 2007). At that time, the 
ERCF contained data on 13,684 CF patients. In general, 
detailed safety assessments of rhDNase indicated that this 
drug is well tolerated. Although development of adverse 
events was the most common reason for withdrawal from 
the studies, the incidence and nature of these events were 
similar in the groups of patients receiving rhDnase and 
those receiving placebo. Only alteration in voice (hoarse-
ness), pharyngitis and laryngitis, was associated with Biologics: Targets & Therapy 2008:2(4) 613
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administration of rhDNase (Aitken et al 1992; Ramsey et al 
1993; Ranasinha et al 1993; Fuchs et al 1994; Eisenberg 
et al 1997).
Clinical efﬁ  cacy assed 
as improvement in pulmonary 
function and reduction 
in respiratory exacerbations
Clinical trials of rhDNase were conducted to test the hypoth-
esis that increased concentrations of polymerized DNA in 
purulent sputum contributes to the acute and chronic com-
plications of CF and that administration of this agent would 
ameliorate such complications. The efﬁ  cacy of aerosolized 
rhDNase in patients with CF has been investigated in a num-
ber of well designed dose-ranging and placebo-controlled 
studies in patients with mild to moderate lung disease. Mild to 
moderate lung disease was deﬁ  ned as a forced vital capacity 
(FVC) 40% of the predicted value.
The Phase II, dose-ranging studies of rhDNase was con-
ducted (Ranasinha et al 1993; Ramsey et al 1993). Clinical 
stable adults and children with CF were eligible for enroll-
ment in these placebo-controlled, double-blind trials. The 
duration of treatment in both studies was 10 days. Improve-
ment in forced expiratory volume in 1 second (FEV1) was 
evident within 3 days of initiating treatment. Ramsey et al 
(1993) found that a 10-day administration of once daily 
0.6 mg, 2.5 mg, or 10.0 mg rhNase signiﬁ  cantly improved 
FEV1 by 10% to 15% compared with placebo. In a second 
study, conducted by Ranasinha et al (1993), a 10-day admin-
istration of twice daily 2.5 mg rhDNase improved FEV1 by 
13.5% compared with placebo.
The ﬁ  rst phase III study with rhDNase was a 24-week, 
multicenter, randomized, double-blind, placebo-controlled 
trial with a parallel-group design and open-label extension 
of 24 weeks (Fuchs et al 1994). In addition to lung function 
the study assessed the effect of rhDNase on the number of 
respiratory tract exacerbations and evaluated the effects of 
rhDNase on quality-of-life measures. Patients were recruited 
from 51 institutions and were eligible if they were 5 years 
of age or older, and had a FVC greater than 40% of the pre-
dicted value. The administration of rhDNase for 24 weeks to 
patients with CF resulted in a modest reduction in the risk of 
exacerbations of respiratory symptoms requiring parenteral 
antibiotics and a slight improvement in lung function. The 
administration of rhDNase also lessened dyspnea, increased 
the perception of general well-being, and decreased the sever-
ity of CF-related symptoms. All patients who completed the 
phase III double-blind study were eligible to participate in 
a 24-week open-label extension of the trial. The positive 
effects of rhDNase therapy were maintained throughout 
the extension. There is no clear consensus on the level of 
improvement in pulmonary function tests as signiﬁ  cant 
clinical response in CF. The mean improvement in FEV1 of 
5.8% observed with long term administration of rhDNase 
were associated with signiﬁ  cant improvements in symptoms 
due to CF airways disease (dyspnea, cough, congestion) and 
more important, with a decline in the incidence of pulmonary 
exacerbations.
In a similar study the use of rhDNase in a 96-week ran-
domized, double blind, placebo-controlled multicenter trial 
involving 574 children with CF and with well preserved lung 
function were reported (Quan et al 2001). In this 2-year study, 
young patients with CF and early lung disease receiving 
rhDNase had improvements in lung function and reduction 
in the risk of exacerbation of respiratory symptoms requir-
ing intravenous antibiotics when compared with patients in 
a placebo group. Lung function in the rhDNase group was 
maintained at or above baseline values for 2 years (Quan 
et al 2001). Despite the milder lung disease in patients in 
this study, the 34% reduction in risk of exacerbation for the 
rhDNase group is similar to the reduction in risk of exacer-
bation seen in the previous 6-month study of patients with 
FVC  40% predicted (Fuchs et al 1994). Because exacer-
bation appears to be a major risk factor for decline in lung 
function, decreasing the number of exacerbations would slow 
the decline in lung function (Konstan et al 2007).
A 12-week study examining the effect of inhaled rhDNase 
in a group of 320 CF patients with advanced lung disease 
(FEV1  40% predicted) showed that patients receiving 
rhDNase had a statistically greater improvement in FEV1 
than placebo group (McCoy et al 1996). The frequency of 
pulmonary exacerbations requiring parenteral antibiotics 
was not signiﬁ  cantly reduced in the rhDNase-treated patients 
compared with placebo recipients. Although a trend toward 
reduction in overall hospitalization was observed in the 
rhDNase group, no signiﬁ  cant difference was seen. This study 
demonstrates that rhDNase is not only effective but also safe in 
CF patients with advanced lung disease (McCoy et al 1996).
To evaluate the long term inﬂ  uence of rhDNase on disease 
progression, Shah et al (2001) conducted a case-controlled 
study with rhDNase over a period of 4 years. A cohort of 
patients with CF who have been treated with rhDNase were 
matched with a control group of patients with CF who 
had not received treatment with rhDNase. The patients 
were matched by pulmonary function, age, and then sex. Biologics: Targets & Therapy 2008:2(4) 614
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There were significantly more infective exacerbations 
per patient year in the control group in comparison to the 
rhDNase group over the 4-year treatment period. Antibiotic 
requirements (days of intravenous antibiotic use per patient 
year) were also signiﬁ  cant greater in the control group com-
pared with the rhDNase group. This case-controlled study 
failed to show a statistically signiﬁ  cant difference in the rate 
of decline in FEV1 between patients treated with rhDNase and 
untreated patients over the study period. However, there was 
a trend to suggest that longer-term treatment with rhDNase 
reduces the rate of decline in FEV1.
Most studies lack even basic microbiological data, but 
a large proportion of exacerbations in pulmonary disease 
in patients with CF are caused by Staphylococcus aureus 
and Pseudomonas aeruginosa (Petersen et al 1981). In a 
12-month study an effect of rhDNase on the load of micro-
bial pathogens in the lower respiratory tract was investigated 
(Frederiksen et al 2006). Overall, the number of positive 
cultures was signiﬁ  cantly higher in the untreated group com-
pared with the treated group. The most striking difference was 
found for S. aureus, with a 12-month prevalence of 30% in 
the untreated group compared with 16% in the treated group 
(p  0.05). The lower infection rate may be associated with 
less respiratory exacerbations and less inﬂ  ammation. In a 
longer perspective, DNase treatment will probably help in 
preventing the gradual tissue damage and irreversible loss of 
lung function, which is the consequence of sustained presence 
of pathogens in the lower respiratory tract.
In a post-marketing surveillance Hodson et al (2003) 
reported the results of treatment with rhDNase by compar-
ing untreated patients (no rhDNase) with treated patients. 
Effects on FEV1 and on number of exacerbations per year 
were studied. In total, 2023 patients were eligible for analy-
sis of FEV1 and 4299 patients were eligible for analysis of 
exacerbations. Overall, untreated patients experienced a 
decrease in mean FEV1% predicted of −1.1 over 1 year and 
−2.3 over 2 years. Patients treated with rhDNase had FEV1 
higher than baseline after 1 year (+2.5% predicted) and 
were stable over the period of 2 years (+0.3% predicted). 
Compared with untreated patients, treated patients had a 
signiﬁ  cant reduction in exacerbation frequency of −0.25. 
This is equivalent to a reduction of 25 exacerbations per 
100 treated patients per year. Younger patients gained most 
from treatment. This result is consistent with the general 
concept that early treatment of CF, before chronic inﬂ  am-
mation has led to irreversible lung damage, may be more 
effective in the long term (Armstrong et al 1995, 2005; 
Khan et al 1995).
Inﬂ  ammation
Studies using spontaneously expectorated sputum have raised 
concerns that rhDNase may increase airway inﬂ  ammation 
by releasing proinﬂ  ammatory cytokines such as IL-8 that are 
bound to DNA in airway secretions (Shah et al 1996; Perks 
et al 2000). The subsequent study was unable to demonstrate 
a promoting effect of rhDNase on IL-8 concentrations (Suri 
et al 2002). Currently, no data are available on the long-term 
effect of rhDNase on lower airway inﬂ  ammation in CF. Given 
the positive effects on both airway clearance and frequency 
of pulmonary exacerbations, rhDNase could also exhibit an 
anti-inﬂ  ammatory effect in CF airways. Paul et al (2004) 
studied lower airway inﬂ  ammation over a 3-year period using 
bronchoalveolar lavage (BAL) in a cohort of patients with 
CF having mild lung disease. A total of 105 patients with 
CF (over 5 years of age) having normal lung function were 
randomized to receive rhDNase (2.5 mg/day) or no rhDNase. 
Patients with a normal percentage of neutrophils in BAL ﬂ  uid 
at baseline were not randomized and served as the control 
group. The percentage of neutrophils in the pooled BAL 
sample was similar in both randomized groups at baseline. 
A signiﬁ  cant increase in neutrophils was observed over the 
3-year study period in both untreated patients and control 
subjects, whereas neutrophils remained unchanged in 
patients treated with rhDNase. Elastase activities and 
interleukin-8 concentrations also increased in untreated 
patients and remained stable in patients on rhDNase. It seems 
that an increase in neutrophilic airway inﬂ  ammation found in 
CF is positively inﬂ  uenced by rhDNase treatment (Paul et al 
2004). These data support earlier ﬁ  ndings that rhDNase has 
a beneﬁ  cial effect on metalloproteases in BAL ﬂ  uid (Ratjen 
et al 2002) and would favor an early use of this drug in 
patients with CF having mild lung disease and support the 
evidence provided by the rhDNase early intervention trial 
study that demonstrated a positive effect of rhDNase on both 
lung function and pulmonary exacerbations in patients with 
CF having mild disease (Quan et al 2001).
rhDNase treatment in young 
children with CF
Studies have shown that rhDNase improves lung function 
and decreases exacerbation rate, and in 1993 rhDNase was 
approved for the management of CF patients with a FVC 
of greater than 40% of predicted in the US, Europe, and 
Australia.
In Europe, rhDNase is approved only for CF patients 
aged 5 years and older, since registration studies were Biologics: Targets & Therapy 2008:2(4) 615
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only performed in this age category. In the US, rhDNase 
is approved for all ages. Surprisingly, no registration stud-
ies have been performed in children below the age of 6 to 
support this registration. Clearly, such studies are difﬁ  cult 
to perform. However, these studies are urgently needed to 
establish safety and efﬁ  cacy especially in infants’ approval 
for Europe and Australia.
CF lung disease begins early in life (Balough et al 1995; 
Khan et al 1995; Kirchner et al 1996; Armstrong et al 2005) 
leading to suggestions that therapy directed at reducing or 
avoiding the development of airway obstruction should be 
started in infants and young children. Elevated DNA concen-
trations have been found in BAL ﬂ  uid from infants with CF 
(Kirchner et al 1996; Ratjen et al 2005), suggesting a role for 
early treatment with rhDNase. Wagener et al (1998) showed 
that aerosolized rhDNase can be delivered to and are present 
in comparable amounts in the lower airways of younger and 
older children. Exposure to rhDNase appears to be safe over 
2 weeks in infants and young children with CF.
The Epidemiologic Registry of Cystic Fibrosis (ERCF) 
was an observational study sponsored by Hoffmann-La 
Roche Ltd that operated in 9 European countries (Austria, 
Belgium, Denmark, France, Germany, Ireland, The Nether-
lands, Sweden, and the UK) between 1994 and 2000. After 
closure of the Epidemiologic Registry of Cystic Fibrosis 
(ERCF), a comprehensive safety analysis of rhDNase was 
performed. A planned subanalysis focused on children 
under 5 years old. During 655 patient-years of follow up 
in 328 ever-treated patients under 5 years old, serious 
adverse events (mostly pulmonary exacerbations of CF) 
were slightly less frequent during treatment conﬁ  rming the 
safety of rhDNase in CF patients of all ages. Children under 
5 years old tolerate rhDNase at least as well as older patients 
(McKenzie et al 2007).
To assess the feasibility of measuring short-term effects 
of inhaled rhDNase on lung function, pulse oximetry, and 
symptom scores in infants and toddlers with stable CF the 
pilot study were performed (Berge et al 2003). Nine CF 
patients (0.7–1.9 years) were treated with nebulized rhDNase 
during 2 weeks. DNase treatment was well tolerated and lung 
function tests (measured with plethysmography and tidal 
rapid thoraco-abdominal compression technique) showed 
signiﬁ  cant increased airway patency after treatment with 
rhDNase, but not after NaCl 0.9%. This pilot study indicates 
that objective assessment of the effects of rhDNase is feasible 
in infants with CF who have little or no respiratory symptoms 
(ten Berge et al 2003). Nasr et al (2001) evaluated the ability 
of high-resolution computerized tomography (HRCT) of the 
chest to determine efﬁ  cacy of inhaled recombinant rhDNase 
in CF patients younger than 5 years of age. A randomized, 
double-blind, placebo-controlled pilot study of 12 patients 
with CF younger than 5 years of age was conducted. The 
mean changes of HRCT scores between the rhDNase and pla-
cebo groups were found to be signiﬁ  cant. There was improve-
ment in the parents’ assessments of patient well-being, with 
improvement in physical activity, decreased cough, sleep 
quality, and appetite in those subjects receiving rhDNase. The 
beneﬁ  t of rhDNase treatment in young CF patients with well 
preserved lung function were conﬁ  rmed by Quan et al (2001) 
in a multicenter, placebo-controlled, 96-week study.
Controversies in rhDNase use
Although clinical trials have shown that rhDNase signiﬁ  -
cantly improves lung function in patients with CF, it does 
not mean that all patients beneﬁ  t from this treatment (Fuchs 
et al 1994; Shah et al 1995; Harms et al 1998). Different 
studies have shown a wide variation in the clinical response 
to rhDNase (Davies et al 1997; Bollert et al 1999; Cobos et al 
2000). Numerous studies have been performed to elucidate 
the reason for the failure of rhDNase in certain CF patients 
and to evaluate strategies to overcome this (Chen et al 1999; 
Sanders et al 2006). Different treatments regimes, according 
optimal timing of rhDNase treatment in relation to phys-
iotherapy, have been studied (van der Giessen et al 2007; 
Wilson et al 2007). Studies to compare different nebulizers 
have been conducted (Fiel et al 1995; Shah et al 1997).
It is a general principle that a registered nebulized drug like 
rhDNase should be aerosolized using only a nebulizer system 
that is considered appropriate by regulatory agencies and the 
responsible pharmaceutical company (Boe et al 2001).
Alternate-day dosing has been suggested (Suri et al 
2002). The authors concluded that rhDnase could be given on 
alternate days as a similar improvement in FEV1 was shown 
compared with daily rhDNase administration. This study 
was conducted over relatively short period (12 weeks) and 
outcomes such as the number of respiratory exacerbations, 
weight gain, and quality of life may need a longer study to 
be able to show the differences.
Conclusion
The most important problem in CF lung disease is chronic 
airway inﬂ  ammation and infection, that starts early in life. 
RhDNase administered as an aerosol reduces the viscosity 
and surface adhesivity of CF sputum. Sputum that is less 
viscous is easier to clear out from the lungs by mucociliary 
and cough clearance. Multiple clinical trials have shown Biologics: Targets & Therapy 2008:2(4) 616
Pressler
that rhDNase is effective as therapy for CF in patients with 
mild to moderate lung disease. It improves lung function 
and decreases the exacerbation rate in adults and children 
with CF.
Importantly, rhDNase is safe to use. Adverse reactions 
attributed to rhDNase are rare.
There is evidence to show that therapy with rhDNase 
over a 1-month period is associated with an improvement 
in lung function in CF, results from a trial lasting 6 months 
also showed the same effect. Therapy over a 2-year period 
signiﬁ  cantly improved FEV1 in children and there was a non-
signiﬁ  cant reduction in the risk of infective exacerbations.
In Europe, rhDNase is approved only for CF patients aged 
5 years and older, since registration studies were performed 
only in this age category.
All clinical indicators, including pathology, the pharma-
cokinetics of distribution, and some pilot efﬁ  cacy studies, 
suggest that rhDNase will be beneﬁ  cial in CF patients under 
5 years old. An adequately powered, placebo-controlled trial 
in CF patients less than 5 years of age is difﬁ  cult to perform. 
However, these studies are urgently needed to establish safety 
and efﬁ  cacy especially in infants.
Use of dornase alfa is becoming increasingly common in 
young CF patients, to maintain lung function at its optimal 
level, reduce the risk of acute and chronic infection, and 
help delay the progression of irreversible lung disease. Early 
intervention is expected to preserve lung function at least as 
effectively as later intervention because irreversible lung 
damage is unlikely to be inﬂ  uenced by any treatment. The 
greatest long-term treatment beneﬁ  t is therefore likely to be 
experienced by the youngest patients. Safety in patients under 
5 years old is at least as good as in older patients. Therefore, 
the beneﬁ  t/risk of dornase alfa in CF patients under 5 years 
old is at least as positive as in older patients.
The question now is not if rhDNase is an effective and 
safe drug. On average patients gain beneﬁ  t from regular 
daily use of rhDNase. Unfortunately, there are no methods 
to more speciﬁ  cally determine who will beneﬁ  t or who 
will not beneﬁ  t from maintenance therapy with rhDNase. 
Despite RhDNase is probably the best investigated drug in 
CF, however, there are weaknesses as well. Clearly, the lack 
of data in young children is problematic. We need also to 
address such problems as use of an appropriate nebulizer. 
Alternative day dosing has been suggested and should be 
investigated further. Low sputum magnesium levels have 
been reported in non-responders to rhDNase and this obser-
vation may have important clinical implications and deserve 
further investigation.
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